These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 34602409)
21. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. May TW; Rambeck B; Jürgens U Ther Drug Monit; 1996 Oct; 18(5):523-31. PubMed ID: 8885114 [TBL] [Abstract][Full Text] [Related]
22. Saliva and serum concentration of lamotrigine in patients with epilepsy. Tsiropoulos I; Kristensen O; Klitgaard NA Ther Drug Monit; 2000 Oct; 22(5):517-21. PubMed ID: 11034255 [TBL] [Abstract][Full Text] [Related]
23. Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. Lardizabal DV; Morris HH; Hovinga CA; Del Mar Carreño M Epilepsia; 2003 Apr; 44(4):536-9. PubMed ID: 12681002 [TBL] [Abstract][Full Text] [Related]
24. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Luszczki JJ; Czuczwar M; Kis J; Krysa J; Pasztelan I; Swiader M; Czuczwar SJ Epilepsia; 2003 Aug; 44(8):1003-13. PubMed ID: 12887431 [TBL] [Abstract][Full Text] [Related]
25. Cav2.3 (R-Type) Calcium Channels are Critical for Mediating Anticonvulsive and Neuroprotective Properties of Lamotrigine In Vivo. Dibué-Adjei M; Kamp MA; Alpdogan S; Tevoufouet EE; Neiss WF; Hescheler J; Schneider T Cell Physiol Biochem; 2017; 44(3):935-947. PubMed ID: 29176325 [TBL] [Abstract][Full Text] [Related]
26. Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. Lalic M; Cvejic J; Popovic J; Bozic K; Golocorbin-Kon S; Al-Salami H; Mikov M Eur J Drug Metab Pharmacokinet; 2009; 34(2):93-9. PubMed ID: 19645218 [TBL] [Abstract][Full Text] [Related]
30. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Armijo JA; Bravo J; Cuadrado A; Herranz JL Ther Drug Monit; 1999 Apr; 21(2):182-90. PubMed ID: 10217338 [TBL] [Abstract][Full Text] [Related]
31. Docosahexaenoic acid prevents resistance to antiepileptic drugs in two animal models of drug-resistant epilepsy. Moezifar M; Sayyah M; Zendehdel M; Gavzan H Nutr Neurosci; 2019 Sep; 22(9):616-624. PubMed ID: 29338667 [No Abstract] [Full Text] [Related]
32. Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world. Li R; Zhou Q; Ou S; Wang Y; Li Y; Xia L; Pan S Epilepsy Res; 2020 Oct; 166():106408. PubMed ID: 32679487 [TBL] [Abstract][Full Text] [Related]
33. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Hirsch LJ; Weintraub D; Du Y; Buchsbaum R; Spencer HT; Hager M; Straka T; Bazil CW; Adams DJ; Resor SR; Morrell MJ Neurology; 2004 Sep; 63(6):1022-6. PubMed ID: 15452293 [TBL] [Abstract][Full Text] [Related]
34. Bidirectional interaction between oral contraception and lamotrigine in women with epilepsy - Role of progestins. Rauchenzauner M; Deichmann S; Pittschieler S; Bergmann M; Prieschl M; Unterberger I; Rösing B; Seger C; Moser C; Wildt L; Luef G Seizure; 2020 Jan; 74():89-92. PubMed ID: 31869755 [TBL] [Abstract][Full Text] [Related]
35. Micellar buccal film for safe and effective control of seizures: Preparation, in vitro characterization, ex vivo permeation studies and in vivo assessment. Salama AH; Basha M; Salama AAA Eur J Pharm Sci; 2021 Nov; 166():105978. PubMed ID: 34418574 [TBL] [Abstract][Full Text] [Related]
36. Influence of imperatorin on the anticonvulsant activity and acute adverse-effect profile of lamotrigine in maximal electroshock-induced seizures and chimney test in mice. Luszczki JJ; Wojda E; Raszewski G; Głowniak K; Czuczwar SJ Pharmacol Rep; 2008; 60(4):566-73. PubMed ID: 18799827 [TBL] [Abstract][Full Text] [Related]
37. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Tompson DJ; Ali I; Oliver-Willwong R; Job S; Zhu L; Lemme F; Hammer AE; Vuong A; Messenheimer JA Epilepsia; 2008 Mar; 49(3):410-7. PubMed ID: 17825077 [TBL] [Abstract][Full Text] [Related]
38. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Doose DR; Brodie MJ; Wilson EA; Chadwick D; Oxbury J; Berry DJ; Schwabe S; Bialer M Epilepsia; 2003 Jul; 44(7):917-22. PubMed ID: 12823574 [TBL] [Abstract][Full Text] [Related]
39. Effects of Chronic Lamotrigine Administration on Maximal Electroshock- Induced Seizures in Mice. Banach M; Borowicz KK CNS Neurol Disord Drug Targets; 2015; 14(7):855-62. PubMed ID: 25714972 [TBL] [Abstract][Full Text] [Related]
40. Influence of administration vehicles and drug formulations on the pharmacokinetic profile of lamotrigine in rats. Castel-Branco MM; Figueiredo IV; Falcão AC; Macedo TR; Caramona MM Fundam Clin Pharmacol; 2002 Oct; 16(5):331-6. PubMed ID: 12602457 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]